ReportsnReports add Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019 to its store.

1. Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and
Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, “Posttraumatic
Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019”.
The report is an essential source of information and analysis on the global Post-Traumatic
Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping
and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The
report also provides insights on the prevalent competitive landscape and the emerging
players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the
global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built
using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by GlobalData’s team of industry experts.
Get more information of this report @ http://www.reportsnreports.com/reports/167924-
posttraumatic-stress-disorder-therapeutics-ptsd-pipeline-assessment-and-market-forecasts-to-
2019.html
Report Details:
Published: June 2012
No. of Pages: 87
Price: Single User License: US $ 3995 Corporate User License: US $ 11985
Scope
The report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder
(PTSD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic Stress
Disorder (PTSD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic
classes.
- Analysis of the current and future competition in the seven key countries Post-Traumatic Stress
Disorder (PTSD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently
researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and
the implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD)
Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of

2. pipeline products and technologies and by identifying the companies with the most robust
pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global Post-Traumatic Stress Disorder
(PTSD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and
strategic partnerships.
- What’s the next big thing in the global Post-Traumatic Stress Disorder (PTSD)
Therapeutics market landscape? – Identify, understand and capitalize.
Major points covered in Table of Contents of this report include:
Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Posttraumatic Stress Disorder Therapeutics - Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 9
2.2.1 Prevalence 9
2.2.2 Pharmacoeconomic Burden 11
2.2.3 Quality of Life (QoL) 12
2.3 Etiology and Pathophysiology 12
2.3.2 Risk Factor 18
2.3.3 Co-morbidities 19
2.4 Signs and Symptoms 20
2.4.1 Re-experiencing Symptoms 20
2.4.2 Avoidance symptoms 20
2.4.3 Hyperarousal Symptoms 20
2.5 Diagnosis 22
2.5.1 Diagnosis Criteria 22
2.5.2 Psychobiologic Approaches 25
2.6 Treatment and Management Options 26
2.6.1 Non-pharmacological Treatment 28
2.6.2 Pharmacological Treatment 28
2.6.3 The US 31
2.6.4 Europe 32
2.7 Referral Pathway 33
2.8 GlobalData Pipeline Report Guidance 34
3 Posttraumatic Stress Disorder Therapeutics - Market Characterization 35

3. 3.1 Overview 35
3.2 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Global 35
3.3 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Global 37
3.4 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The US 38
3.5 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The US 39
3.6 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - France 40
3.7 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - France 41
3.8 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Germany 42
3.9 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Germany 43
3.10 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Italy 44
3.11 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Italy 45
3.12 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Spain 46
3.13 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Spain 47
3.14 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The UK 48
3.15 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The UK 49
3.16 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Japan 50
3.17 PTSD Therapeutics Market Forecast (2011-2019) - Japan 51
3.18 Drivers and Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52
3.18.1 Drivers for the Posttraumatic Stress Disorder Therapeutics Market 52
3.18.2 Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52
3.19 Opportunity and Unmet Need Analysis 53
3.20 Key Takeaway 54
4 Posttraumatic Stress Disorder Therapeutics - Competitive Assessment 55
4.1 Overview 55
4.2 Strategic Competitor Assessment 55
4.3 Product Profiles for the Major Marketed Products in the Posttraumatic Stress Disorder Therapeutics
Market 56
4.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 56
4.3.2 Paxil (paroxetine) 57
4.3.3 Zoloft (sertraline) 58
4.3.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 59
4.3.5 Atypical Antipsychotics 60
4.4 Key Takeaway 60
5 Posttraumatic Stress Disorder Therapeutics - Pipeline Assessment 61
5.1 Overview 61
5.2 Strategic Pipeline Assessment 61
5.3 Posttraumatic Stress Disorder Therapeutics Pipeline - Pipeline by Phases of Development 62
5.3.1 Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline 62
5.3.2 Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline 63
5.3.3 Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline 63
5.3.4 Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline 63
5.3.5 Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline 64
5.3.6 Technology Trends Analytic Framework 64
5.4 Posttraumatic Stress Disorder Therapeutics Market -Pipeline by Mechanism of Action 66
5.5 Molecule Profile for Promising Drugs under Clinical Development 67
5.5.1 Avlocardyl (propranolol) 67
5.6 Key Takeaway 67
6 Posttraumatic Stress Disorder Therapeutics - Clinical Trials Mapping 68
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 68

4. 6.2 Clinical Trials by Phase 69
6.3 Clinical Trials by Trial Status 70
6.4 Prominent Sponsors 71
6.5 Top Companies Participating in Posttraumatic Stress Disorder Therapeutics Clinical Trials 72
7 Posttraumatic Stress Disorder Therapeutics - Strategic Assessment 73
7.1 Key Events Impacting the Future Market 73
7.2 Posttraumatic Stress Disorder Therapeutics: Implications for Future Market Competition 74
8 Posttraumatic Stress Disorder Therapeutics - Future Players 75
8.1 Introduction 75
8.2 Company Profiles 76
8.2.1 Synosia Therapeutics/Biotie Therapies Corp. 76
8.2.2 Columbia Northwest Pharmaceuticals 77
8.2.3 Marinus Pharmaceuticals, Inc. 77
8.2.4 Nanotherapeutics, Inc. 78
9 Posttraumatic Stress Disorder Therapeutics - Licensing and Partnership Deals 79
10 Posttraumatic Stress Disorder Therapeutics - Appendix 80
10.1 Market Definitions 80
10.2 Abbreviations 80
10.3 Bibliography 81
10.4 Research Methodology 83
10.4.1 Coverage 83
10.4.2 Secondary Research 84
10.4.3 Forecasting 84
10.4.4 Primary Research 86
10.4.5 Expert Panel Validation 87
10.5 Contact Us 87
10.6 Disclaimer 87
Related Reports @ http://www.reportsnreports.com/publisher/globaldata/
Contact:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: + 1 888 391 5441
sales@reportsandreports.com
Connect With Us: